I wish posters here would pay attention to reality
Post# of 75355
(Total Views: 627)
Posted On: 05/06/2018 10:20:35 PM
I wish posters here would pay attention to reality. Talk of a NYSE uplist, $1.00 pps, being bought out by big soda, and distribution into foreign countries are, for the foreseeable future, ridiculous to even discuss. Consider the facts——all verifiable.
1. Rmhb has over $30,000,000.00 in shareholder deficit. That’s money taken from shareholders no longer reflected in the market cap. It’s gone and neither the management, directors or consultants have suffered financially as a result. In fact they are all quite well paid.
2. RMHB has had less than $10k average monthly sales over the past 8 months. That’s deserving of a market cap of maybe $2 million, at the very best, meaning the appropriate pps, right now, should be in the .001 range.
3. There is functionally, fundamentally and realistically no way for them to grow sales at a pace to achieve a market cap of $300 million at anytime in the next two years. And, that market cap would equate to a pps of .20, assuming the ongoing dilution stops immediately. Of course, the only way the dilution stops immediately is if Rmhb has another source of revenue to keep their operation moving. With average per quarter costs, per SEC quarterly and annual filings, that run to hundreds of thousands of dollars, the likelihood of this moving anywhere but sideways or down is ludicrous.
4. The supposed Mexico private label deal was quite obviously conceived to support the Equity Funding Agreement, as that is the vehicle to provide the cash while RMHB attempts to market products in the crowded CBD arena. Google “CBD products for sale” and your search will deliver over 12 million results. Just try to find HEMPd in that ocean. For them to reach a market cap of $300 million, an unachievable CBD market share would need to be reached. They don’t have their own products, given that they simply print labels for an existing line. They are attempting to move CBD products through their own website and an obscure distributor called M & S Up North. Through Amazon and eBay, they are attempting to market the same products, only hemp infused, rather than CBD.
5. We know nothing about CBD Alimentos, the distributor looking to buy private labelled drinks from RMHB. Four months since the agreement was announced, we still have no information on Alimentos and the company refuses to enlighten us. Once again, the products in this deal are not RMHB products. Alimentos, if they exist, have complete control over formula, ingredients, taste and flavor. In effect they are developing their own product and are paying for it by using an RMHB segregated account as a conduit for their own money.
All of this is fact supported. There is much, much more, which includes the hostile usurping of the Lilly Li Series A control block. Pay attention to the facts people. They are not the enemy.
I’m not well liked here....that I can deal with. However, many of my solid, fact based analyses have been deleted, depriving investors of due diligence that could assist them in making strategic trading decisions.
If you disagree with my analysis, please offer a cogent rebuttal and let’s have a friendly discourse.
1. Rmhb has over $30,000,000.00 in shareholder deficit. That’s money taken from shareholders no longer reflected in the market cap. It’s gone and neither the management, directors or consultants have suffered financially as a result. In fact they are all quite well paid.
2. RMHB has had less than $10k average monthly sales over the past 8 months. That’s deserving of a market cap of maybe $2 million, at the very best, meaning the appropriate pps, right now, should be in the .001 range.
3. There is functionally, fundamentally and realistically no way for them to grow sales at a pace to achieve a market cap of $300 million at anytime in the next two years. And, that market cap would equate to a pps of .20, assuming the ongoing dilution stops immediately. Of course, the only way the dilution stops immediately is if Rmhb has another source of revenue to keep their operation moving. With average per quarter costs, per SEC quarterly and annual filings, that run to hundreds of thousands of dollars, the likelihood of this moving anywhere but sideways or down is ludicrous.
4. The supposed Mexico private label deal was quite obviously conceived to support the Equity Funding Agreement, as that is the vehicle to provide the cash while RMHB attempts to market products in the crowded CBD arena. Google “CBD products for sale” and your search will deliver over 12 million results. Just try to find HEMPd in that ocean. For them to reach a market cap of $300 million, an unachievable CBD market share would need to be reached. They don’t have their own products, given that they simply print labels for an existing line. They are attempting to move CBD products through their own website and an obscure distributor called M & S Up North. Through Amazon and eBay, they are attempting to market the same products, only hemp infused, rather than CBD.
5. We know nothing about CBD Alimentos, the distributor looking to buy private labelled drinks from RMHB. Four months since the agreement was announced, we still have no information on Alimentos and the company refuses to enlighten us. Once again, the products in this deal are not RMHB products. Alimentos, if they exist, have complete control over formula, ingredients, taste and flavor. In effect they are developing their own product and are paying for it by using an RMHB segregated account as a conduit for their own money.
All of this is fact supported. There is much, much more, which includes the hostile usurping of the Lilly Li Series A control block. Pay attention to the facts people. They are not the enemy.
I’m not well liked here....that I can deal with. However, many of my solid, fact based analyses have been deleted, depriving investors of due diligence that could assist them in making strategic trading decisions.
If you disagree with my analysis, please offer a cogent rebuttal and let’s have a friendly discourse.
(10)
(2)